GlassScriptPhysician profile
Casey Benjamin Rendon
NPI 1578004792
$9,265.76
in general payments reported to CMS, 2019-2025
17 companies · $4,887 in 2025
The $4,887 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $717 · 2023: $1,243 · 2024: $2,183 · 2025: $4,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,438 · Consulting Fee: $3,200 · Travel and Lodging: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,438.43 |
| Consulting Fee | $3,200.00 |
| Travel and Lodging | $1,675.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $4,157.48 | 2025 | |
| Medtronic, INC. | $1,377.18 | 2022-2024 | Minimed 780g |
| Abbott Laboratories | $934.18 | 2023-2025 | Freestyle Libre 3, Afinion 2, Freestyle Libre 2 |
| Novo Nordisk INC | $797.09 | 2021-2025 | Ozempic |
| Dexcom, INC. | $430.79 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.33 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $219.01 | 2023-2024 | Korlym |
| Amryt Pharma Holdings LTD | $178.41 | 2023 | Mycapssa |
| Beta Bionics, INC. | $157.33 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $144.22 | 2024 | |
| Amgen INC. | $121.78 | 2024 | Tepezza |
| Xeris Pharmaceuticals, INC. | $118.40 | 2022 | |
| Lifescan, INC. | $109.49 | 2022 | |
| Angiodynamics, INC. | $88.75 | 2022 | |
| Ascendis Pharma Endocrinology INC | $81.06 | 2025 | Yorvipath |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $70.27 | 2022 | |
| Tandem Diabetes Care, INC. | $36.99 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Rendon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.